Cua Ata Lagatuu
FDA investigator
Appears on 1 document from 2017, mostly at sites in Belgium. Most often cites general requirements (21 CFR 211.160).
- 1
- Documents on file
- 8.0
- Observations per 483
- 2017
- First seen
- 2017
- Most recent
What they cite most
From 8 observations- 21 CFR 211.160General requirements2
- 21 CFR 211.22Responsibilities of quality control unit2
- 21 CFR 211.165Testing and release for distribution1
- 21 CFR 211.166Stability testing1
- 21 CFR 211.198Complaint files1
Activity by year
2017: 1
Where
Belgium 1
Often inspects with
Is Cua Ata Lagatuu coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2017-01-27 | 483 UCB Pharma S.A.Jan 27, 2017 · Braine-l'Alleud, Belgium | Braine-l'Alleud, Belgium | 8 |
About this profile
What does Cua Ata Lagatuu inspect?
Cua Ata Lagatuu appears on 1 document on file covering 1 site, mostly in Belgium.
What do they cite most often?
21 CFR 211.160 (general requirements), followed by 21 CFR 211.22 and 21 CFR 211.165.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Cua Ata Lagatuu is dated Jan 27, 2017.